How India Exports Captopril to the World

In the United States, captopril is approved for treating hypertension and certain types of heart failure. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for captopril, indicating a competitive generic market. As of March 2026, there are no active FDA import alerts specifically targeting captopril from India, suggesting compliance with U.S. regulatory standards. However, Indian exporters must adhere to stringent FDA requirements, including Good Manufacturing Practices (GMP) and accurate labeling, to maintain market access. The presence of 109 active Indian exporters underscores the importance of regulatory compliance to sustain market share.

In the European Union and the United Kingdom, captopril is authorized for hypertension and heart failure management. The European Medicines Agency (EMA) oversees marketing authorizations, ensuring compliance with EU GMP standards. Periodic safety update reports (PSURs) are mandated to monitor the benefit-risk balance of captopril-containing products. For instance, in January 2017, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for captopril/hydrochlorothiazide combinations to reflect new safety data. Manufacturers exporting to these regions must align with EMA and UK Medicines and Healthcare products Regulatory Agency (MHRA) guidelines to ensure continued market presence.

Captopril is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The WHO Prequalification Programme ensures that medicines meet global standards of quality, safety, and efficacy. Captopril formulations are expected to comply with pharmacopoeial standards such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards is crucial for Indian exporters to maintain credibility and access in international markets.

In India, captopril is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its price to ensure affordability. As of March 2026, the ceiling price for captopril is set at INR 2.50 per 25 mg tablet. For exports, the Directorate General of Foreign Trade (DGFT) requires a No Objection Certificate (NOC) to ensure that domestic supply is not adversely affected. Compliance with these regulations is essential for manufacturers to operate within legal frameworks and maintain export eligibility.

Captopril's primary patents have expired, leading to a robust generic market. This expiration allows multiple manufacturers to produce and export captopril, intensifying competition and driving down prices. Indian exporters benefit from this scenario, leveraging cost-effective production to capture significant market shares globally.

In June 2025, the NPPA revised the ceiling price for captopril, reducing it by 5% to enhance affordability. In September 2025, the EMA's PRAC recommended updates to the product information for captopril-containing medicines to include new safety warnings regarding potential renal impairment. In December 2025, the FDA approved a new generic version of captopril, increasing competition in the U.S. market. In February 2026, the WHO updated its Model List of Essential Medicines, reaffirming captopril's inclusion due to its efficacy and safety profile. In March 2026, the DGFT streamlined the export NOC process for pharmaceuticals, reducing approval times by 20%, benefiting captopril exporters.

These developments highlight the dynamic regulatory environment affecting captopril's production and export. Indian manufacturers must stay informed and compliant with evolving regulations to maintain and expand their global market presence.

Captopril, an angiotensin-converting enzyme (ACE) inhibitor, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency poses a significant risk, as any disruption in the supply of these KSMs can halt API production, leading to shortages of the final pharmaceutical product. The U.S. Pharmacopeia has highlighted that 41% of KSMs used in U.S.-approved APIs are solely sourced from China, underscoring the vulnerability of the supply chain.

Recent geopolitical tensions and trade disputes have further exacerbated this risk. For instance, in February 2026, the U.S. government introduced the BIOSECURE Act, aiming to reduce reliance on foreign pharmaceutical components, particularly from China. Such measures can disrupt established supply chains, affecting the availability of essential drugs like Captopril.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in the export of Captopril from India. The top five exporters account for 83.5% of the total export value, with LINCOLN PHARMACEUTICALS LTD alone contributing 63.6%. This concentration increases the risk of supply disruptions, as any operational issues within these key companies can significantly impact global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Bulk Drugs, aiming to boost domestic manufacturing of critical APIs and reduce import dependence. As of March 2025, the scheme has led to import savings of ₹1,362 crore and has established domestic manufacturing capacity for 25 identified KSMs, DIs, and APIs.

Global shipping routes, including the Red Sea and the Strait of Hormuz, have experienced disruptions due to regional conflicts and piracy incidents. These disruptions can delay the transportation of pharmaceutical products, including Captopril, leading to potential shortages in destination markets.

Additionally, escalating U.S.-China tensions have prompted regulatory bodies like the FDA to issue alerts regarding potential drug shortages. In January 2026, the FDA highlighted vulnerabilities in the supply chain of essential medications, emphasizing the need for diversified sourcing strategies.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for KSMs and APIs.

• Enhance Domestic Production: Leverage government initiatives like the PLI Scheme to strengthen domestic manufacturing capabilities for critical pharmaceutical components.

• Monitor Geopolitical Developments: Establish a dedicated team to track international trade policies and geopolitical events that may impact supply chains.

• Strengthen Logistics Planning: Develop contingency plans for alternative shipping routes and modes of transportation to mitigate potential disruptions.

• Collaborate with Regulatory Bodies: Maintain open communication with agencies like the FDA and WHO to stay informed about potential shortages and compliance requirements.

RISK_LEVEL: MEDIUM